Ganitumab
Based on 1 publication(s) in Google Scholar
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.00%
- CAS No.: 905703-97-1
- Masse moléculaire:145.743 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ganitumab
More
Activité biologique
Human IgG1 kappa
Human
IGF1R/CD221
Ganitumab (AMG 479; 0.032-500 nM; 10 min; CT26 cells) binds mIGF1R and inhibits IGF1- and IGF2-mediated activation of mIGF1R[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CT26 cells
-
Concentration:0.032-500 nM
-
Incubation Time:10 minutes
-
Result:Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner.
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Naïve and tumor-bearing mice[1]
-
Dosage:1 mg/dose
-
Administration:Intraperitoneal injection
-
Result:Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.
-
Animal Model:Male athymic nude mice[1]
-
Dosage:300 μg/dose
-
Administration:Intraperitoneal injection, twice per week for a total of five doses
-
Result:Had significantly higher serum glucose levels than hIgG1-pretreated mice.
Increased serum levels of mIGF1, mIGFPB3 and mGH.
-
Animal Model:Female athymic nude mice[1]
-
Dosage:300 μg/dose
-
Administration:Intraperitoneal injection, twice per week for a total of five doses
-
Result:Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 MCF-7 cells with Ganitumab (HY-P99294, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control. -
Loaded Ganitumab on AHC2 biosensor, can bind IGF-I R Protein, Human (HEK293, His-Avi, HY-P78458) with an affinity constant of 8.072E-10 M as determined in BLI assay.
Chemical Information
-
CAS No. 905703-97-1
-
Appearance Liquid
-
Masse moléculaire 145.743 kDa
-
Color Colorless to light yellow
-
SMILES
[Ganitumab]
-
Synonyms
AMG 479; Human Anti-IGF1R Recombinant Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)